Form 4: Korro Bio Director Timothy Pearson Granted 6,010 Stock Options

Korro Bio, Inc. Director Timothy R. Pearson was granted 6,010 stock options with an exercise price of $14.87, vesting on the earlier of one year from the grant date or the next annual meeting of stockholders.

Summary

• Timothy R. Pearson, a Director of Korro Bio, Inc. (KRRO), was granted 6,010 stock options.
• The options have an exercise price of $14.87 per share.
• The grant date for these options was June 11, 2025.
• The options are set to vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders, contingent on his continued service as a non-employee director.
• The options expire on June 10, 2035.
• Following this transaction, Mr. Pearson beneficially owns 6,010 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for corporate governance and alignment of interests, indicating a standard compensation practice aimed at retention and performance incentive. It's a routine event, not a major catalyst, hence a moderately positive score.

Positives

• The grant of stock options to Director Timothy R. Pearson aligns his interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule, tied to continued service, promotes retention of key board members.

Risks

• The value of the stock options is subject to the future market price of Korro Bio, Inc. common stock, meaning the options may not be "in the money" if the stock price does not exceed the exercise price.
• Vesting is contingent on continued service, meaning the options could be forfeited if the director's service ceases before the vesting date.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider's equity transaction.

Management Comments

• This document is a regulatory filing and does not contain direct quotes or paraphrased statements from company management.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain experienced board members and align their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 6,010 stock options to a non-employee director with a vesting period tied to continued service is a standard compensation practice.
• While specific comparable companies or projects are not detailed in this filing, such grants are typical for directors in similar-sized biotech firms, aiming to incentivize long-term commitment and performance.
• The exercise price of $14.87 would typically be set at the fair market value of the stock on the grant date, which is a common benchmark.

Corporate Governance

Related Party Transactions

• The grant of 6,010 stock options to Timothy R. Pearson, a Director of Korro Bio, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.

Next Steps

• Timothy R. Pearson's continued service as a non-employee director to meet vesting conditions.
• The options will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders.

Key Dates

Keywords

Korro Bio, KRRO, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership, Timothy Pearson